missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. 30171624

PD-L1 Antibody (garivulimab) [Janelia Fluor™ 525], Novus Biologicals™

Human Monoclonal Antibody

Brand:  Novus Biologicals (Bio-Techne) NBP3-28444JF525

3217.25 NOK valid until 2025-12-16
BEST PRICE on Promo! Use promo code "24090" to get your promotional price.

Product Code. 30171624

  • 3790.00 NOK / 0.10mL

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

PD-L1 Monoclonal antibody specifically detects PD-L1 in Human samples. It is validated for Flow Cytometry,ELISA,Functional Assay
TRUSTED_SUSTAINABILITY
Specifications

Specifications

PD-L1
Monoclonal
Janelia Fluor 525
Avelumab, B7-H, B7-H1, B7H1PDCD1L1, CD274 antigenMGC142294, CD274 molecule, PDCD1LG1MGC142296, PD-L1, PD-L1B7 homolog 1, PDL1PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1
B7-H1/ PD-L1/ CD274
0.1 mL
Autoimmune Diseases, Cancer, Cellular Markers, Checkpoint signaling, Immune System Diseases, Immunology, Signal Transduction, Tumor Biomarkers, Tumor Suppressors
29126
Store at 4°C in the dark.
IgG1
Flow Cytometry, ELISA, Functional Assay
garivulimab
50mM Sodium Borate
Human
Protein A purified
RUO
Primary
Human
Purified
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.